Acumen Pharmaceuticals (ABOS) Non-Current Debt (2023 - 2026)

Acumen Pharmaceuticals (ABOS) has 4 years of Non-Current Debt data on file, last reported at $16.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 42.68% year-over-year to $16.9 million; the trailing twelve-month figure through Mar 2026 stood at $16.9 million (down 42.68% YoY), and the FY2025 full-year result was $22.4 million, down 23.87% from the prior year.
• Non-Current Debt eased to $16.9 million in Q1 2026, from $22.4 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $30.2 million in Q1 2024 to a low of $16.9 million in Q1 2026.
• A 4-year average of $27.4 million and a median of $29.5 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt increased 1.71% in 2025 and sank 42.68% in 2026, its largest moves.
• Tracing ABOS's Non-Current Debt over 4 years: stood at $29.9 million in 2023, then dropped by 1.6% to $29.4 million in 2024, then fell by 23.87% to $22.4 million in 2025, then declined by 24.43% to $16.9 million in 2026.
• Business Quant data shows ABOS's Non-Current Debt at $16.9 million in Q1 2026, $22.4 million in Q4 2025, and $27.1 million in Q3 2025.